Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Open-label, Multicenter Phase I/II Study to Evaluate the Safety and Anti-tumor Activity of ANV600 as Single Agent and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)

NCT06470763 is registered in ClinicalTrials.gov with Anaveon AG as lead sponsor.

NCT NCT06470763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06470763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Open-label, Multicenter Phase I/II Study to Evaluate the Safety and Anti-tumor Activity of ANV600 as Single Agent and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)
Lead sponsor
Anaveon AG
Phase
Phase 1/2
Overall status
Completed
Start date
July 1, 2024
Completion date
June 22, 2026
Enrollment
63 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor